Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Novartis-India-Limited"

5 News Found

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
News | October 30, 2025

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr

Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025

Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr
News | July 30, 2025

Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr

Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr
News | May 12, 2024

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr

Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr
News | January 28, 2024

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr

Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
News | July 28, 2022

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.

Latest Stories

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Alkem Foundation and IIT Bombay collaborate to set up advanced research centre for immuno-therapeutics, regenerative medicines

Merck Foundation launches $22 million initiative to improve cardiovascular care in US

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Dr. Umesh N Jindal Director, Jindal IVF
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India

Packaging